Evidence sheet: added ribociclib × invasive disease-free survival — NATALEE interim and final results

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Comparative efficacyAre the original subclaim and grade distinguished from the parent judgment context?Required	The selected existing claim is ‘Improved invasive disease-free survival’, with subclaim grade B and the note that one large trial crossed its prespecified boundary. The parent is B, 76 points and Caution. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Absent subclaim score, status and axes are not filled with parent values. No new judgment, blanket D grade or independence certification is provided.	Separate preservation of the selected question, grade and note and the original parent judgment	Link additional materials separately to the selected question and the parent context.
2	Partly verified	Full text not readStored summary read	N02 · Comparative efficacyWhat is the actual early-breast-cancer population and scope of baseline conditions?Required	NATALEE is an international phase 3 trial comparing added ribociclib in stage 2 or 3 HR-positive, HER2-negative early breast cancer. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The summary lacks details of nodal status, detailed risk eligibility, baseline treatment, population composition and original group denominators. Findings are not extended to metastatic cancer or other stages or types.	Original eligibility, HR/HER2, stage, sex, baseline characteristics and denominators	Obtain original eligibility, baseline, previous-treatment and group-specific participant materials.
3	Partly verified	Full text not readStored summary read	N03 · Comparative efficacyWhat is the actual comparison between added treatment and endocrine therapy alone?Required	Ribociclib plus endocrine therapy was compared with endocrine therapy alone. Existing topic classifications preserve aromatase inhibitors and endocrine therapy. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This is not converted to ribociclib alone, ineffectiveness of endocrine therapy or direct superiority over other drugs. Original tables on specific endocrine drugs, concomitant treatment and exposure changes have not been read.	Original intervention and comparator, shared endocrine therapy, concomitant treatment and actual exposure	Obtain original group-specific interventions, shared endocrine therapy, concomitant treatment and changes.
4	Partly verified	Full text not readStored summary read	N04 · Comparative efficacyAre the study dose and 3-year plan distinguished from actual treatment completion?Required	The original conditions were a study plan of 400 mg for 3 weeks on and 1 week off, repeated for 3 years. This is historical exposure preserved in the existing review summary. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This does not certify that all participants completed 3 years or advise individuals on dose, schedule or treatment. Distributions of actual treatment, adherence, discontinuation and dose reduction have not been read.	Original study exposure, planned duration, actual adherence, reduction or discontinuation, and denominators	Obtain original plans, actual exposure, completion, discontinuation, dose reduction and denominators.
5	Partly verified	Full text not readStored summary read	N05 · Comparative efficacyIs concomitant exposure in premenopausal women and men recorded separately?Required	The existing review summary states that premenopausal women and men also received goserelin. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This is not converted to a goserelin-only effect, identical exposure for everyone or individual treatment suitability. Population-specific group denominators, original effects and interactions have not been read.	Population-specific concomitant treatment, original denominators, actual exposure and analyses	Obtain population-specific shared or added exposure, denominators and prespecified-analysis materials.
6	Partly verified	Full text not readStored summary read	N06 · Comparative efficacyWhat are the 5,101 randomized participants and outcome-specific denominators or risk sets?Required	NATALEE randomized 5,101 participants; the existing review summary records 1:1 allocation and ITT analysis. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new group counts, total events, dropout rates or risk sets are calculated. The original ITT description alone does not newly certify outcome-specific missingness or complete follow-up.	Randomization, original group counts, ITT, follow-up and outcome-specific denominators	Obtain original participant flow, group allocation, ITT, risk sets, censoring and denominators.
7	Partly verified	Full text not readStored summary read	N07 · Comparative efficacyAre the original roles of open-label design, central allocation and objective events distinguished?Required	The existing review summary records a central interactive allocation system, 1:1 allocation, open-label design, objective recurrence, invasive cancer or death events, and ITT as historical B0 evidence. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This is not converted into a new certification of blinding in all assessment or analysis, or absence of bias. Original procedural details have not been read externally.	Allocation, concealment, adjudicators, blinding and event ascertainment	Obtain original allocation, ascertainment, adjudication, analysis, censoring and bias materials.
8	Partly verified	Full text not readStored summary read	N08 · Comparative efficacyAre the composite iDFS events distinguished from overall survival?Required	The original primary endpoint is STEEP v1.0 iDFS, a composite of recurrence, invasive cancer and death. The stored summary records overall-survival data as still immature. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Reduction in composite events is not transferred to reduced all-cause death, longer survival time or definite cure. Original tables of individual components and all-cause deaths have not been read.	Original STEEP definition, components, people or events, all-cause death and duration	Obtain original STEEP definitions, component-specific events, overall survival, durations and denominators separately.
9	Partly verified	Full text not readStored summary read	N09 · Comparative efficacyAre the interim 3-year survival rates, HR, CI and two-sided P preserved as recorded?Required	At interim analysis, 3-year iDFS was 90.4% versus 87.1%, HR 0.75(95% CI 0.62~0.91), two-sided P=.003. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Survival rates are not converted to simple event proportions or OS values. No new absolute difference, NNT, risk ratio, reversed HR or P value is calculated.	Original analysis timing, 3-year estimates, HR, CI, tests and denominators	Obtain original estimation methods, group risk sets, censoring, denominators, CI and models.
10	Partly verified	Full text not readStored summary read	N10 · Comparative efficacyAre the prespecified one-sided boundary and two-sided P distinguished?Required	The existing review summary records two-sided P=.003 and the protocol's one-sided P<.0128 boundary, stating that the prespecified superiority boundary was crossed. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Two-sided and one-sided values are not made identical, and no new test, boundary or exemption from multiplicity is certified. Original registration, planning and boundary documents have not been read.	Protocol, interim analysis, test direction, alpha spending, boundary and changes	Obtain original interim-analysis plans, boundaries, direction, alpha spending and change history.
11	Partly verified	Full text not readStored summary read	N11 · Comparative efficacyAre the final 33.3-month analysis and 226/283 events distinguished from interim values?Required	The prespecified final analysis had median follow-up of 33.3 months, 226 versus 283 events, HR 0.749(95% CI 0.628~0.892), P=.0012. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Median follow-up of 33.3 months is not equated with the time point of the 3-year survival estimate, and events from the two reports are not added. No new final 3-year rate, event total or OS result is created.	Analysis cutoff date, follow-up statistics, events, original effects and denominators	Obtain original analysis cutoffs, follow-up distributions, risk sets, models and event mapping.
12	Partly verified	Full text not readStored summary read	N12 · Comparative efficacyAre interim and final reports kept from being added as new independent confirmation?Required	The Slamon2024 interim report and Hortobagyi2025 final report concern the same NATALEE trial. The stored summary records one confirmatory trial of ribociclib itself. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The 2 reports, follow-up and two subclaim outcomes are not added as new independent trials or participants. Final independent and participant totals are not recorded.	The same trial and population, follow-up reports, individual outcomes and sibling-sheet relationships	Connect additional reports through original registration, population, timing and overlap relationships.
13	Unverified	Full text not readStored summary read	N13 · Comparative efficacyWhat gaps remain in overall-survival event maturity, effects, CI, P and hierarchy?Required	The note for the longer-overall-survival subclaim states that the data remain immature. The existing review summary and safety text preserve this limitation. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The 226/283 iDFS events, HR or CI are not used to fill OS events or effects. The summary lacks OS deaths, HR, CI, P, information fraction and cutoff date. Immaturity is not converted to a definite zero effect.	Original deaths, follow-up, OS effect of interest, denominators, plans and maturity	Obtain original OS events, denominators, follow-up, prespecified hierarchy, boundaries, models and CI.
14	Partly verified	Full text not readStored summary read	N14 · Comparative efficacyIs the original scope of iDFS improvement kept from extending to long-term survival or cure?Required	The original note for subclaim B states that one large trial crossed its prespecified boundary. Original interim and final iDFS results are recorded. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These original results do not establish overall survival, cure or permanent prevention after treatment ends. No new individual effect or application recommendation is provided.	Original composite endpoint, clinical components, duration and direct long-term outcomes	Obtain original component-specific outcomes, long-term iDFS, OS and functional outcomes separately.
15	Partly verified	Full text not readStored summary read	N15 · Comparative efficacyAre actual exposure completion, survival follow-up and long-term persistence distinguished?Required	The original intervention plan was 3 years, while median follow-up in the final iDFS analysis was 33.3 months; these are different time descriptions. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These two durations are not combined as identical treatment or follow-up for everyone, or a persistent long-term effect after treatment ends.	Planned exposure, actual completion, follow-up duration and post-discontinuation outcomes	Obtain original actual exposure, follow-up, censoring and long-term outcomes after discontinuation.
16	Unverified	Full text not readStored summary read	N16 · Comparative efficacyDo information gaps remain for subgroups, stage or sex application, and multiplicity?Required	The original population was stage 2 or 3 HR-positive, HER2-negative disease; concomitant goserelin exposure in premenopausal women and men is recorded. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new population-specific effects, drug suitability, individual predictions or prespecified interaction results are created. Detailed subgroup plans, original denominators and multiplicity have not been read.	Prespecified subgroups, interactions, models, original denominators and effects	Obtain prespecified subgroup, interaction, denominator, CI and multiplicity materials.
17	Partly verified	Full text not readStored summary read	N17 · Comparative efficacyWhat are the other drug, trial and level of wording in PALLAS?Required	PALLAS is summarized in the stored record as a phase 3 trial with 5,796 participants, Pfizer and cooperative study groups, and no added benefit from palbociclib. R01 R02 R04	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. It is not used as direct replication of ribociclib or a direct comparison of superiority between drugs. Detailed PALLAS effects, CI, P, duration, eligibility and a separate citation link are absent from the existing review summary.	Palbociclib population, intervention, comparison, denominators, original effects and bibliography	Obtain original PALLAS reports, population, comparison, effects, duration, denominators and bibliography separately.
18	Partly verified	Full text not readStored summary read	N18 · Comparative efficacyAre the repeated CI, drug and original comparison scope of PENELOPE-B preserved?Required	PENELOPE-B was a double-blind, placebo-controlled phase 3 palbociclib trial with 1,250 participants, HR 0.93(95% repeated CI 0.74~1.17), P=.525. R01 R02 R03	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The repeated CI is not newly certified as the same analysis as an ordinary CI, and these values do not replace ribociclib OS or iDFS. Original follow-up, eligibility and planning details have not been read.	Original drug, double blinding, placebo, effects, repeated CI and denominators	Obtain original repeated CI, plans, population, follow-up, denominators and effects.
19	Partly verified	Full text not readStored summary read	N19 · Comparative efficacyAre monarchE's other drug and 4-year results distinguished from NATALEE?Required	The existing review summary records monarchE as an abemaciclib trial with 5,637 participants, 4-year rates 85.8% versus 79.4%, HR 0.664(95% CI 0.578~0.762), supported by Eli Lilly. R01 R02 R05	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These values do not fill ribociclib's 4-year or OS results or create a direct superiority or equivalence comparison between drugs. A separate citation link, original P value and detailed eligibility are absent from the existing review summary.	Original drug, population, duration, denominators, effects and independent relationships	Obtain original monarchE bibliography, eligibility, comparison, duration, effects and plans separately.
20	Partly verified	Full text not readStored summary read	N20 · Comparative efficacyAre different within-class results kept from becoming a class-wide effect or new independent replication?Required	The stored summary contrasts two null palbociclib trials with positive ribociclib NATALEE and abemaciclib monarchE results, limiting generalization across drugs. R01 R02 R03 R04 R05	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Positive or null results for other drugs are not used as independent NATALEE replication, zero ribociclib effect, class-wide benefit or direct superiority. Study participants and reports are not added together.	Drug-specific questions, eligibility, comparators, durations and report or participant relationships	Obtain drug-specific direct questions, original eligibility, duration, comparators and overlap relationships.
21	Partly verified	Full text not readStored summary read	N21 · Comparative efficacyAre Novartis, TRIO, unreported public support and company roles distinguished?Required	NATALEE was supported by Novartis and co-supervised by TRIO; the existing Korean article records no separate public grant as reported. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. TRIO supervision is not converted into certification of funding, drug supply or analytical independence. Details of drug or in-kind provision, employee authors, external analysis and writing roles are absent from the existing review summary or unread.	Cash, drugs or in-kind support, affiliations, external analysis, supervision and writing roles	Obtain original disclosures of funding, supply, affiliations, supervision, analysis and writing separately.
22	Partly verified	Full text not readStored summary read	N22 · Comparative efficacyAre funding and independence information for other-drug trials kept within their original scope?Required	Original funding information records Pfizer and cooperative study groups for PALLAS, the GBG and Pfizer development program for PENELOPE-B, and Eli Lilly for monarchE. R01 R02 R04 R03 R05	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Participation of study groups alone does not newly certify absence of company in-kind support or employee authors, or independence of external analysis. Original role details have not been read.	Each trial's funding, in-kind support, authors, analysis and roles	Obtain each trial's original support, products, affiliations, analysis and writing relationships.
23	Partly verified	Full text not readStored summary read	N23 · Supplementary harm evidenceWhat collection gaps remain for neutropenia, liver-related adverse events and QT prolongation?Required	The stored safety record lists neutropenia, liver-related adverse events and QT prolongation; the parent's safety status is Caution. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new harm rates, grades, risk differences, P, CI, safety ranking or monitoring instructions are created. Original details of people or events, collection, denominators and relatedness have not been read.	Each harm's definition, grade, people or events, original denominators, exposure and relatedness	Obtain original harm types, grades, collection, group denominators, exposure, relatedness and discontinuation.
24	Unverified	Full text not readStored summary read	N24 · Supplementary harm evidenceAre harm-related discontinuation, dose reduction, actual exposure and ITT distinguished?Required	The stored summary records planned exposure of 3 years and ITT analysis, and describes harm types. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These do not support new calculations of exposure completion for everyone, discontinuation rates, adherent-participant effects or survival differences caused by harms.	Original discontinuation, dose reduction, adherence, exposure, harms and event mapping	Obtain original actual exposure, harm-related discontinuation, dose reduction, adherence, follow-up and event connections.
25	Unverified	Full text not readStored summary read	N25 · Supplementary harm evidenceAre rare or long-term harms and replication of harms in other drugs kept from being newly established?Required	The currently designated stored summary records some harm types and still-immature OS, while other-drug trials are used as iDFS contrasts. R01 R02 R03 R04 R05	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Absence of harm tables is not converted to absence of rare harms or long-term safety, and iDFS findings for other drugs do not certify identical harms. No treatment, monitoring or dose recommendations are created.	Long-term harms, exposure, duration, denominators and direct drug-specific comparisons	Obtain drug-specific direct harm, long-term exposure, collection, denominator and follow-up materials.
26	Partly verified	Full text not readStored summary read	N26 · Comparative efficacyAre original registration, three bibliography URLs and two evidence records without bibliography distinguished?Required	The three existing citations provide NATALEE interim and final URLs and a PENELOPE-B URL, while PALLAS and monarchE have only existing evidence-list information. Each original registration identifier is preserved. R01 R02 R03 R04 R05	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new bibliography, DOI or URL is created for PALLAS or monarchE. External abstracts, full texts, registration, protocols and SAP remain unread; separate link testing was not performed.	Each report, existing links, registration identifiers and access status	Connect additional user-provided original materials by report type, bibliography and actual access status.
27	Partly verified	Full text not readStored summary read	N27 · Comparative efficacyAre Korean and English articles, axes, reference dates, corrections, empty values and preparation status preserved?Supplementary	2026-08-26, empty correction and deliberation records, the parent's B76/Caution, axes, Korean and English articles, subclaim B/D and notes are preserved as recorded. R01 R02	Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Original B0, registration agreement and confirmatory wording are historical records, not new review certification. Subclaim absences are not filled; original pending-review or preparation-eligibility indicators are candidate history.	Distinguishing the entire parent, selected subclaim, original languages and history from the current preparation	Preserve original texts before connecting additional user materials or decisions as separate events.

No items match your search or filter.

27 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Stage 2 or 3 HR-positive, HER2-negative early breast cancer; original NATALEE eligibility and baseline details unread
Ingredient, formulation and route: Historical study exposure to ribociclib plus endocrine therapy; no treatment-selection recommendation
Dose: The original 400 mg, 3 weeks on/1 week off, 3 years and population-specific goserelin are preserved as historical stored-summary records; no dose, administration or suitability instructions are created
Comparator: Endocrine therapy alone; other-drug trials contrast within-class results and are not direct comparisons between drugs
Measured outcome: STEEP v1.0 iDFS improvement; original interim and final effects distinguished from immature OS
Duration: Distinguishing 3-year iDFS estimates, 3-year planned exposure and final median follow-up of 33.3 months; OS-specific follow-up and maturity details unread
Questions outside this scope: Converting composite iDFS events to OS, cure or permanent prevention; Adding interim or final reports and other drugs as independent replication of ribociclib; Combining 3-year estimates, planned exposure and median follow-up of 33.3 months; Copying effects of other drugs into ribociclib OS values; Recommendations on treatment, dose, monitoring or suitability

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Slamon D, et al. N Engl J Med. 2024;390:1080-1091. PMID: 38507751.

PubMed

Material type: Report linked through an existing citation
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: Three-year rates 90.4% versus 87.1%, HR 0.75(95% CI 0.62~0.91), P=.003; final events 226 versus 283, HR 0.749(0.628~0.892), P=.0012
Record level: The two reports from the same NATALEE trial share the integrated evidence-list results; this is not a comparison with each external report
Study overlap and independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
local_summary	Existing link preserved	Summary read	Summary read	Stored parent-verdict summary
abstract	Existing link preserved	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
fulltext	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
registration	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
protocol_sap	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review

R02 · Hortobagyi GN, et al. Ann Oncol. 2025;36:149-157. PMID: 39442617.

PubMed

Material type: Report linked through an existing citation
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: Three-year rates 90.4% versus 87.1%, HR 0.75(95% CI 0.62~0.91), P=.003; final events 226 versus 283, HR 0.749(0.628~0.892), P=.0012
Record level: The two reports from the same NATALEE trial share the integrated evidence-list results; this is not a comparison with each external report
Study overlap and independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
local_summary	Existing link preserved	Summary read	Summary read	Stored parent-verdict summary
abstract	Existing link preserved	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
fulltext	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
registration	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
protocol_sap	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review

R03 · Loibl S, et al. J Clin Oncol. 2021. PMID: 33793299.

PubMed

Material type: Report linked through an existing citation
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: HR 0.93(95% repeated CI 0.74~1.17), P=.525
Record level: Other-drug results in the existing evidence list; not independent replication of ribociclib
Study overlap and independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
local_summary	Existing link preserved	Summary read	Summary read	Stored parent-verdict summary
abstract	Existing link preserved	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
fulltext	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
registration	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
protocol_sap	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review

R04 · PALLAS palbociclib trial

Material type: Study information recorded in the existing evidence list; bibliography not acquired
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: No added benefit from palbociclib
Record level: Other-drug results in the existing evidence list; not independent replication of ribociclib
Study overlap and independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
local_summary	Existing link preserved	Summary read	Summary read	Stored parent-verdict summary
abstract	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
fulltext	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
registration	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
protocol_sap	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review

R05 · monarchE abemaciclib trial

Material type: Study information recorded in the existing evidence list; bibliography not acquired
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: Four-year rates 85.8% versus 79.4%, HR 0.664(95% CI 0.578~0.762)
Record level: Other-drug results in the existing evidence list; not independent replication of ribociclib
Study overlap and independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
local_summary	Existing link preserved	Summary read	Summary read	Stored parent-verdict summary
abstract	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
fulltext	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
registration	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
protocol_sap	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review

Report counts versus independent study counts

The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Are the original subclaim and grade distinguished from the parent judgment context?

Required materials and conditions: Separate preservation of the selected question, grade and note and the original parent judgment
Conditions for verification: Separate preservation of the selected question, grade and note and the original parent judgment
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N02 · What is the actual early-breast-cancer population and scope of baseline conditions?

Required materials and conditions: Original eligibility, HR/HER2, stage, sex, baseline characteristics and denominators
Conditions for verification: Original eligibility, HR/HER2, stage, sex, baseline characteristics and denominators
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N03 · What is the actual comparison between added treatment and endocrine therapy alone?

Required materials and conditions: Original intervention and comparator, shared endocrine therapy, concomitant treatment and actual exposure
Conditions for verification: Original intervention and comparator, shared endocrine therapy, concomitant treatment and actual exposure
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N04 · Are the study dose and 3-year plan distinguished from actual treatment completion?

Required materials and conditions: Original study exposure, planned duration, actual adherence, reduction or discontinuation, and denominators
Conditions for verification: Original study exposure, planned duration, actual adherence, reduction or discontinuation, and denominators
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N05 · Is concomitant exposure in premenopausal women and men recorded separately?

Required materials and conditions: Population-specific concomitant treatment, original denominators, actual exposure and analyses
Conditions for verification: Population-specific concomitant treatment, original denominators, actual exposure and analyses
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N06 · What are the 5,101 randomized participants and outcome-specific denominators or risk sets?

Required materials and conditions: Randomization, original group counts, ITT, follow-up and outcome-specific denominators
Conditions for verification: Randomization, original group counts, ITT, follow-up and outcome-specific denominators
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N07 · Are the original roles of open-label design, central allocation and objective events distinguished?

Required materials and conditions: Allocation, concealment, adjudicators, blinding and event ascertainment
Conditions for verification: Allocation, concealment, adjudicators, blinding and event ascertainment
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N08 · Are the composite iDFS events distinguished from overall survival?

Required materials and conditions: Original STEEP definition, components, people or events, all-cause death and duration
Conditions for verification: Original STEEP definition, components, people or events, all-cause death and duration
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N09 · Are the interim 3-year survival rates, HR, CI and two-sided P preserved as recorded?

Required materials and conditions: Original analysis timing, 3-year estimates, HR, CI, tests and denominators
Conditions for verification: Original analysis timing, 3-year estimates, HR, CI, tests and denominators
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N10 · Are the prespecified one-sided boundary and two-sided P distinguished?

Required materials and conditions: Protocol, interim analysis, test direction, alpha spending, boundary and changes
Conditions for verification: Protocol, interim analysis, test direction, alpha spending, boundary and changes
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N11 · Are the final 33.3-month analysis and 226/283 events distinguished from interim values?

Required materials and conditions: Analysis cutoff date, follow-up statistics, events, original effects and denominators
Conditions for verification: Analysis cutoff date, follow-up statistics, events, original effects and denominators
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N12 · Are interim and final reports kept from being added as new independent confirmation?

Required materials and conditions: The same trial and population, follow-up reports, individual outcomes and sibling-sheet relationships
Conditions for verification: The same trial and population, follow-up reports, individual outcomes and sibling-sheet relationships
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N13 · What gaps remain in overall-survival event maturity, effects, CI, P and hierarchy?

Required materials and conditions: Original deaths, follow-up, OS effect of interest, denominators, plans and maturity
Conditions for verification: Original deaths, follow-up, OS effect of interest, denominators, plans and maturity
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N14 · Is the original scope of iDFS improvement kept from extending to long-term survival or cure?

Required materials and conditions: Original composite endpoint, clinical components, duration and direct long-term outcomes
Conditions for verification: Original composite endpoint, clinical components, duration and direct long-term outcomes
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N15 · Are actual exposure completion, survival follow-up and long-term persistence distinguished?

Required materials and conditions: Planned exposure, actual completion, follow-up duration and post-discontinuation outcomes
Conditions for verification: Planned exposure, actual completion, follow-up duration and post-discontinuation outcomes
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N16 · Do information gaps remain for subgroups, stage or sex application, and multiplicity?

Required materials and conditions: Prespecified subgroups, interactions, models, original denominators and effects
Conditions for verification: Prespecified subgroups, interactions, models, original denominators and effects
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N17 · What are the other drug, trial and level of wording in PALLAS?

Required materials and conditions: Palbociclib population, intervention, comparison, denominators, original effects and bibliography
Conditions for verification: Palbociclib population, intervention, comparison, denominators, original effects and bibliography
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N18 · Are the repeated CI, drug and original comparison scope of PENELOPE-B preserved?

Required materials and conditions: Original drug, double blinding, placebo, effects, repeated CI and denominators
Conditions for verification: Original drug, double blinding, placebo, effects, repeated CI and denominators
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N19 · Are monarchE's other drug and 4-year results distinguished from NATALEE?

Required materials and conditions: Original drug, population, duration, denominators, effects and independent relationships
Conditions for verification: Original drug, population, duration, denominators, effects and independent relationships
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N20 · Are different within-class results kept from becoming a class-wide effect or new independent replication?

Required materials and conditions: Drug-specific questions, eligibility, comparators, durations and report or participant relationships
Conditions for verification: Drug-specific questions, eligibility, comparators, durations and report or participant relationships
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N21 · Are Novartis, TRIO, unreported public support and company roles distinguished?

Required materials and conditions: Cash, drugs or in-kind support, affiliations, external analysis, supervision and writing roles
Conditions for verification: Cash, drugs or in-kind support, affiliations, external analysis, supervision and writing roles
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N22 · Are funding and independence information for other-drug trials kept within their original scope?

Required materials and conditions: Each trial's funding, in-kind support, authors, analysis and roles
Conditions for verification: Each trial's funding, in-kind support, authors, analysis and roles
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N23 · What collection gaps remain for neutropenia, liver-related adverse events and QT prolongation?

Required materials and conditions: Each harm's definition, grade, people or events, original denominators, exposure and relatedness
Conditions for verification: Each harm's definition, grade, people or events, original denominators, exposure and relatedness
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N24 · Are harm-related discontinuation, dose reduction, actual exposure and ITT distinguished?

Required materials and conditions: Original discontinuation, dose reduction, adherence, exposure, harms and event mapping
Conditions for verification: Original discontinuation, dose reduction, adherence, exposure, harms and event mapping
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N25 · Are rare or long-term harms and replication of harms in other drugs kept from being newly established?

Required materials and conditions: Long-term harms, exposure, duration, denominators and direct drug-specific comparisons
Conditions for verification: Long-term harms, exposure, duration, denominators and direct drug-specific comparisons
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N26 · Are original registration, three bibliography URLs and two evidence records without bibliography distinguished?

Required materials and conditions: Each report, existing links, registration identifiers and access status
Conditions for verification: Each report, existing links, registration identifiers and access status
Requirement and applicability: Required
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

N27 · Are Korean and English articles, axes, reference dates, corrections, empty values and preparation status preserved?

Required materials and conditions: Distinguishing the entire parent, selected subclaim, original languages and history from the current preparation
Conditions for verification: Distinguishing the entire parent, selected subclaim, original languages and history from the current preparation
Requirement and applicability: Supplementary
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Referenced methods: Improved invasive disease-free survival

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

What the statuses mean

Partly verified: Some information exists in the preserved review summary, with detailed original materials still unverified; no certification of a passed review or clinical efficacy
Unverified: Detailed materials for the selected condition could not be established within the stored scope; this does not mean zero effect, zero studies or safety
Review incomplete: Existing content review pending
Met: Use only within the relevant conditions after existing content review; no automatic designation in this preparation
Not reported: Distinguish only within materials actually read; do not turn unread external materials into unreported findings
Inaccessible: Not applied during this preparation because actual access was not tested
Not applicable: Use with a reason for non-applicability based on an explicit question boundary
Conflicting data: Judge after actual material comparison; review was not performed during this preparation
Insufficient evidence for the conditions: Do not use as a clinical grade encompassing currently unread materials

Change history

2026-10-10 · Public page/material version 1.0

Public pages and materials were prepared from the existing 27 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Are the original subclaim and grade distinguished from the parent judgment context?

Current findings: The selected existing claim is ‘Improved invasive disease-free survival’, with subclaim grade B and the note that one large trial crossed its prespecified boundary. The parent is B, 76 points and Caution.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Absent subclaim score, status and axes are not filled with parent values. No new judgment, blanket D grade or independence certification is provided.
Reason for missing information: Absent subclaim score, status and axes are not filled with parent values. No new judgment, blanket D grade or independence certification is provided.
Required materials and conditions: Separate preservation of the selected question, grade and note and the original parent judgment
Materials to obtain first: Absent subclaim score, status and axes are not filled with parent values. No new judgment, blanket D grade or independence certification is provided.
Further research: Link additional materials separately to the selected question and the parent context.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Separate preservation of the selected question, grade and note and the original parent judgment
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N02 · What is the actual early-breast-cancer population and scope of baseline conditions?

Current findings: NATALEE is an international phase 3 trial comparing added ribociclib in stage 2 or 3 HR-positive, HER2-negative early breast cancer.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The summary lacks details of nodal status, detailed risk eligibility, baseline treatment, population composition and original group denominators. Findings are not extended to metastatic cancer or other stages or types.
Reason for missing information: The summary lacks details of nodal status, detailed risk eligibility, baseline treatment, population composition and original group denominators. Findings are not extended to metastatic cancer or other stages or types.
Required materials and conditions: Original eligibility, HR/HER2, stage, sex, baseline characteristics and denominators
Materials to obtain first: The summary lacks details of nodal status, detailed risk eligibility, baseline treatment, population composition and original group denominators. Findings are not extended to metastatic cancer or other stages or types.
Further research: Obtain original eligibility, baseline, previous-treatment and group-specific participant materials.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original eligibility, HR/HER2, stage, sex, baseline characteristics and denominators
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N03 · What is the actual comparison between added treatment and endocrine therapy alone?

Current findings: Ribociclib plus endocrine therapy was compared with endocrine therapy alone. Existing topic classifications preserve aromatase inhibitors and endocrine therapy.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This is not converted to ribociclib alone, ineffectiveness of endocrine therapy or direct superiority over other drugs. Original tables on specific endocrine drugs, concomitant treatment and exposure changes have not been read.
Reason for missing information: This is not converted to ribociclib alone, ineffectiveness of endocrine therapy or direct superiority over other drugs. Original tables on specific endocrine drugs, concomitant treatment and exposure changes have not been read.
Required materials and conditions: Original intervention and comparator, shared endocrine therapy, concomitant treatment and actual exposure
Materials to obtain first: This is not converted to ribociclib alone, ineffectiveness of endocrine therapy or direct superiority over other drugs. Original tables on specific endocrine drugs, concomitant treatment and exposure changes have not been read.
Further research: Obtain original group-specific interventions, shared endocrine therapy, concomitant treatment and changes.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original intervention and comparator, shared endocrine therapy, concomitant treatment and actual exposure
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N04 · Are the study dose and 3-year plan distinguished from actual treatment completion?

Current findings: The original conditions were a study plan of 400 mg for 3 weeks on and 1 week off, repeated for 3 years. This is historical exposure preserved in the existing review summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This does not certify that all participants completed 3 years or advise individuals on dose, schedule or treatment. Distributions of actual treatment, adherence, discontinuation and dose reduction have not been read.
Reason for missing information: This does not certify that all participants completed 3 years or advise individuals on dose, schedule or treatment. Distributions of actual treatment, adherence, discontinuation and dose reduction have not been read.
Required materials and conditions: Original study exposure, planned duration, actual adherence, reduction or discontinuation, and denominators
Materials to obtain first: This does not certify that all participants completed 3 years or advise individuals on dose, schedule or treatment. Distributions of actual treatment, adherence, discontinuation and dose reduction have not been read.
Further research: Obtain original plans, actual exposure, completion, discontinuation, dose reduction and denominators.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original study exposure, planned duration, actual adherence, reduction or discontinuation, and denominators
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N05 · Is concomitant exposure in premenopausal women and men recorded separately?

Current findings: The existing review summary states that premenopausal women and men also received goserelin.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This is not converted to a goserelin-only effect, identical exposure for everyone or individual treatment suitability. Population-specific group denominators, original effects and interactions have not been read.
Reason for missing information: This is not converted to a goserelin-only effect, identical exposure for everyone or individual treatment suitability. Population-specific group denominators, original effects and interactions have not been read.
Required materials and conditions: Population-specific concomitant treatment, original denominators, actual exposure and analyses
Materials to obtain first: This is not converted to a goserelin-only effect, identical exposure for everyone or individual treatment suitability. Population-specific group denominators, original effects and interactions have not been read.
Further research: Obtain population-specific shared or added exposure, denominators and prespecified-analysis materials.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Population-specific concomitant treatment, original denominators, actual exposure and analyses
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N06 · What are the 5,101 randomized participants and outcome-specific denominators or risk sets?

Current findings: NATALEE randomized 5,101 participants; the existing review summary records 1:1 allocation and ITT analysis.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new group counts, total events, dropout rates or risk sets are calculated. The original ITT description alone does not newly certify outcome-specific missingness or complete follow-up.
Reason for missing information: No new group counts, total events, dropout rates or risk sets are calculated. The original ITT description alone does not newly certify outcome-specific missingness or complete follow-up.
Required materials and conditions: Randomization, original group counts, ITT, follow-up and outcome-specific denominators
Materials to obtain first: No new group counts, total events, dropout rates or risk sets are calculated. The original ITT description alone does not newly certify outcome-specific missingness or complete follow-up.
Further research: Obtain original participant flow, group allocation, ITT, risk sets, censoring and denominators.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Randomization, original group counts, ITT, follow-up and outcome-specific denominators
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N07 · Are the original roles of open-label design, central allocation and objective events distinguished?

Current findings: The existing review summary records a central interactive allocation system, 1:1 allocation, open-label design, objective recurrence, invasive cancer or death events, and ITT as historical B0 evidence.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This is not converted into a new certification of blinding in all assessment or analysis, or absence of bias. Original procedural details have not been read externally.
Reason for missing information: This is not converted into a new certification of blinding in all assessment or analysis, or absence of bias. Original procedural details have not been read externally.
Required materials and conditions: Allocation, concealment, adjudicators, blinding and event ascertainment
Materials to obtain first: This is not converted into a new certification of blinding in all assessment or analysis, or absence of bias. Original procedural details have not been read externally.
Further research: Obtain original allocation, ascertainment, adjudication, analysis, censoring and bias materials.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Allocation, concealment, adjudicators, blinding and event ascertainment
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N08 · Are the composite iDFS events distinguished from overall survival?

Current findings: The original primary endpoint is STEEP v1.0 iDFS, a composite of recurrence, invasive cancer and death. The stored summary records overall-survival data as still immature.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Reduction in composite events is not transferred to reduced all-cause death, longer survival time or definite cure. Original tables of individual components and all-cause deaths have not been read.
Reason for missing information: Reduction in composite events is not transferred to reduced all-cause death, longer survival time or definite cure. Original tables of individual components and all-cause deaths have not been read.
Required materials and conditions: Original STEEP definition, components, people or events, all-cause death and duration
Materials to obtain first: Reduction in composite events is not transferred to reduced all-cause death, longer survival time or definite cure. Original tables of individual components and all-cause deaths have not been read.
Further research: Obtain original STEEP definitions, component-specific events, overall survival, durations and denominators separately.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original STEEP definition, components, people or events, all-cause death and duration
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N09 · Are the interim 3-year survival rates, HR, CI and two-sided P preserved as recorded?

Current findings: At interim analysis, 3-year iDFS was 90.4% versus 87.1%, HR 0.75(95% CI 0.62~0.91), two-sided P=.003.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Survival rates are not converted to simple event proportions or OS values. No new absolute difference, NNT, risk ratio, reversed HR or P value is calculated.
Reason for missing information: Survival rates are not converted to simple event proportions or OS values. No new absolute difference, NNT, risk ratio, reversed HR or P value is calculated.
Required materials and conditions: Original analysis timing, 3-year estimates, HR, CI, tests and denominators
Materials to obtain first: Survival rates are not converted to simple event proportions or OS values. No new absolute difference, NNT, risk ratio, reversed HR or P value is calculated.
Further research: Obtain original estimation methods, group risk sets, censoring, denominators, CI and models.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original analysis timing, 3-year estimates, HR, CI, tests and denominators
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N10 · Are the prespecified one-sided boundary and two-sided P distinguished?

Current findings: The existing review summary records two-sided P=.003 and the protocol's one-sided P<.0128 boundary, stating that the prespecified superiority boundary was crossed.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Two-sided and one-sided values are not made identical, and no new test, boundary or exemption from multiplicity is certified. Original registration, planning and boundary documents have not been read.
Reason for missing information: Two-sided and one-sided values are not made identical, and no new test, boundary or exemption from multiplicity is certified. Original registration, planning and boundary documents have not been read.
Required materials and conditions: Protocol, interim analysis, test direction, alpha spending, boundary and changes
Materials to obtain first: Two-sided and one-sided values are not made identical, and no new test, boundary or exemption from multiplicity is certified. Original registration, planning and boundary documents have not been read.
Further research: Obtain original interim-analysis plans, boundaries, direction, alpha spending and change history.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Protocol, interim analysis, test direction, alpha spending, boundary and changes
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N11 · Are the final 33.3-month analysis and 226/283 events distinguished from interim values?

Current findings: The prespecified final analysis had median follow-up of 33.3 months, 226 versus 283 events, HR 0.749(95% CI 0.628~0.892), P=.0012.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Median follow-up of 33.3 months is not equated with the time point of the 3-year survival estimate, and events from the two reports are not added. No new final 3-year rate, event total or OS result is created.
Reason for missing information: Median follow-up of 33.3 months is not equated with the time point of the 3-year survival estimate, and events from the two reports are not added. No new final 3-year rate, event total or OS result is created.
Required materials and conditions: Analysis cutoff date, follow-up statistics, events, original effects and denominators
Materials to obtain first: Median follow-up of 33.3 months is not equated with the time point of the 3-year survival estimate, and events from the two reports are not added. No new final 3-year rate, event total or OS result is created.
Further research: Obtain original analysis cutoffs, follow-up distributions, risk sets, models and event mapping.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Analysis cutoff date, follow-up statistics, events, original effects and denominators
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N12 · Are interim and final reports kept from being added as new independent confirmation?

Current findings: The Slamon2024 interim report and Hortobagyi2025 final report concern the same NATALEE trial. The stored summary records one confirmatory trial of ribociclib itself.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The 2 reports, follow-up and two subclaim outcomes are not added as new independent trials or participants. Final independent and participant totals are not recorded.
Reason for missing information: The 2 reports, follow-up and two subclaim outcomes are not added as new independent trials or participants. Final independent and participant totals are not recorded.
Required materials and conditions: The same trial and population, follow-up reports, individual outcomes and sibling-sheet relationships
Materials to obtain first: The 2 reports, follow-up and two subclaim outcomes are not added as new independent trials or participants. Final independent and participant totals are not recorded.
Further research: Connect additional reports through original registration, population, timing and overlap relationships.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: The same trial and population, follow-up reports, individual outcomes and sibling-sheet relationships
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N13 · What gaps remain in overall-survival event maturity, effects, CI, P and hierarchy?

Current findings: The note for the longer-overall-survival subclaim states that the data remain immature. The existing review summary and safety text preserve this limitation.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The 226/283 iDFS events, HR or CI are not used to fill OS events or effects. The summary lacks OS deaths, HR, CI, P, information fraction and cutoff date. Immaturity is not converted to a definite zero effect.
Reason for missing information: The 226/283 iDFS events, HR or CI are not used to fill OS events or effects. The summary lacks OS deaths, HR, CI, P, information fraction and cutoff date. Immaturity is not converted to a definite zero effect.
Required materials and conditions: Original deaths, follow-up, OS effect of interest, denominators, plans and maturity
Materials to obtain first: The 226/283 iDFS events, HR or CI are not used to fill OS events or effects. The summary lacks OS deaths, HR, CI, P, information fraction and cutoff date. Immaturity is not converted to a definite zero effect.
Further research: Obtain original OS events, denominators, follow-up, prespecified hierarchy, boundaries, models and CI.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original deaths, follow-up, OS effect of interest, denominators, plans and maturity
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N14 · Is the original scope of iDFS improvement kept from extending to long-term survival or cure?

Current findings: The original note for subclaim B states that one large trial crossed its prespecified boundary. Original interim and final iDFS results are recorded.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These original results do not establish overall survival, cure or permanent prevention after treatment ends. No new individual effect or application recommendation is provided.
Reason for missing information: These original results do not establish overall survival, cure or permanent prevention after treatment ends. No new individual effect or application recommendation is provided.
Required materials and conditions: Original composite endpoint, clinical components, duration and direct long-term outcomes
Materials to obtain first: These original results do not establish overall survival, cure or permanent prevention after treatment ends. No new individual effect or application recommendation is provided.
Further research: Obtain original component-specific outcomes, long-term iDFS, OS and functional outcomes separately.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original composite endpoint, clinical components, duration and direct long-term outcomes
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N15 · Are actual exposure completion, survival follow-up and long-term persistence distinguished?

Current findings: The original intervention plan was 3 years, while median follow-up in the final iDFS analysis was 33.3 months; these are different time descriptions.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These two durations are not combined as identical treatment or follow-up for everyone, or a persistent long-term effect after treatment ends.
Reason for missing information: These two durations are not combined as identical treatment or follow-up for everyone, or a persistent long-term effect after treatment ends.
Required materials and conditions: Planned exposure, actual completion, follow-up duration and post-discontinuation outcomes
Materials to obtain first: These two durations are not combined as identical treatment or follow-up for everyone, or a persistent long-term effect after treatment ends.
Further research: Obtain original actual exposure, follow-up, censoring and long-term outcomes after discontinuation.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Planned exposure, actual completion, follow-up duration and post-discontinuation outcomes
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N16 · Do information gaps remain for subgroups, stage or sex application, and multiplicity?

Current findings: The original population was stage 2 or 3 HR-positive, HER2-negative disease; concomitant goserelin exposure in premenopausal women and men is recorded.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new population-specific effects, drug suitability, individual predictions or prespecified interaction results are created. Detailed subgroup plans, original denominators and multiplicity have not been read.
Reason for missing information: No new population-specific effects, drug suitability, individual predictions or prespecified interaction results are created. Detailed subgroup plans, original denominators and multiplicity have not been read.
Required materials and conditions: Prespecified subgroups, interactions, models, original denominators and effects
Materials to obtain first: No new population-specific effects, drug suitability, individual predictions or prespecified interaction results are created. Detailed subgroup plans, original denominators and multiplicity have not been read.
Further research: Obtain prespecified subgroup, interaction, denominator, CI and multiplicity materials.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Prespecified subgroups, interactions, models, original denominators and effects
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N17 · What are the other drug, trial and level of wording in PALLAS?

Current findings: PALLAS is summarized in the stored record as a phase 3 trial with 5,796 participants, Pfizer and cooperative study groups, and no added benefit from palbociclib.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. It is not used as direct replication of ribociclib or a direct comparison of superiority between drugs. Detailed PALLAS effects, CI, P, duration, eligibility and a separate citation link are absent from the existing review summary.
Reason for missing information: It is not used as direct replication of ribociclib or a direct comparison of superiority between drugs. Detailed PALLAS effects, CI, P, duration, eligibility and a separate citation link are absent from the existing review summary.
Required materials and conditions: Palbociclib population, intervention, comparison, denominators, original effects and bibliography
Materials to obtain first: It is not used as direct replication of ribociclib or a direct comparison of superiority between drugs. Detailed PALLAS effects, CI, P, duration, eligibility and a separate citation link are absent from the existing review summary.
Further research: Obtain original PALLAS reports, population, comparison, effects, duration, denominators and bibliography separately.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Palbociclib population, intervention, comparison, denominators, original effects and bibliography
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02 R04

N18 · Are the repeated CI, drug and original comparison scope of PENELOPE-B preserved?

Current findings: PENELOPE-B was a double-blind, placebo-controlled phase 3 palbociclib trial with 1,250 participants, HR 0.93(95% repeated CI 0.74~1.17), P=.525.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The repeated CI is not newly certified as the same analysis as an ordinary CI, and these values do not replace ribociclib OS or iDFS. Original follow-up, eligibility and planning details have not been read.
Reason for missing information: The repeated CI is not newly certified as the same analysis as an ordinary CI, and these values do not replace ribociclib OS or iDFS. Original follow-up, eligibility and planning details have not been read.
Required materials and conditions: Original drug, double blinding, placebo, effects, repeated CI and denominators
Materials to obtain first: The repeated CI is not newly certified as the same analysis as an ordinary CI, and these values do not replace ribociclib OS or iDFS. Original follow-up, eligibility and planning details have not been read.
Further research: Obtain original repeated CI, plans, population, follow-up, denominators and effects.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original drug, double blinding, placebo, effects, repeated CI and denominators
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02 R03

N19 · Are monarchE's other drug and 4-year results distinguished from NATALEE?

Current findings: The existing review summary records monarchE as an abemaciclib trial with 5,637 participants, 4-year rates 85.8% versus 79.4%, HR 0.664(95% CI 0.578~0.762), supported by Eli Lilly.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These values do not fill ribociclib's 4-year or OS results or create a direct superiority or equivalence comparison between drugs. A separate citation link, original P value and detailed eligibility are absent from the existing review summary.
Reason for missing information: These values do not fill ribociclib's 4-year or OS results or create a direct superiority or equivalence comparison between drugs. A separate citation link, original P value and detailed eligibility are absent from the existing review summary.
Required materials and conditions: Original drug, population, duration, denominators, effects and independent relationships
Materials to obtain first: These values do not fill ribociclib's 4-year or OS results or create a direct superiority or equivalence comparison between drugs. A separate citation link, original P value and detailed eligibility are absent from the existing review summary.
Further research: Obtain original monarchE bibliography, eligibility, comparison, duration, effects and plans separately.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original drug, population, duration, denominators, effects and independent relationships
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02 R05

N20 · Are different within-class results kept from becoming a class-wide effect or new independent replication?

Current findings: The stored summary contrasts two null palbociclib trials with positive ribociclib NATALEE and abemaciclib monarchE results, limiting generalization across drugs.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Positive or null results for other drugs are not used as independent NATALEE replication, zero ribociclib effect, class-wide benefit or direct superiority. Study participants and reports are not added together.
Reason for missing information: Positive or null results for other drugs are not used as independent NATALEE replication, zero ribociclib effect, class-wide benefit or direct superiority. Study participants and reports are not added together.
Required materials and conditions: Drug-specific questions, eligibility, comparators, durations and report or participant relationships
Materials to obtain first: Positive or null results for other drugs are not used as independent NATALEE replication, zero ribociclib effect, class-wide benefit or direct superiority. Study participants and reports are not added together.
Further research: Obtain drug-specific direct questions, original eligibility, duration, comparators and overlap relationships.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Drug-specific questions, eligibility, comparators, durations and report or participant relationships
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02 R03 R04 R05

N21 · Are Novartis, TRIO, unreported public support and company roles distinguished?

Current findings: NATALEE was supported by Novartis and co-supervised by TRIO; the existing Korean article records no separate public grant as reported.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. TRIO supervision is not converted into certification of funding, drug supply or analytical independence. Details of drug or in-kind provision, employee authors, external analysis and writing roles are absent from the existing review summary or unread.
Reason for missing information: TRIO supervision is not converted into certification of funding, drug supply or analytical independence. Details of drug or in-kind provision, employee authors, external analysis and writing roles are absent from the existing review summary or unread.
Required materials and conditions: Cash, drugs or in-kind support, affiliations, external analysis, supervision and writing roles
Materials to obtain first: TRIO supervision is not converted into certification of funding, drug supply or analytical independence. Details of drug or in-kind provision, employee authors, external analysis and writing roles are absent from the existing review summary or unread.
Further research: Obtain original disclosures of funding, supply, affiliations, supervision, analysis and writing separately.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Cash, drugs or in-kind support, affiliations, external analysis, supervision and writing roles
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N22 · Are funding and independence information for other-drug trials kept within their original scope?

Current findings: Original funding information records Pfizer and cooperative study groups for PALLAS, the GBG and Pfizer development program for PENELOPE-B, and Eli Lilly for monarchE.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Participation of study groups alone does not newly certify absence of company in-kind support or employee authors, or independence of external analysis. Original role details have not been read.
Reason for missing information: Participation of study groups alone does not newly certify absence of company in-kind support or employee authors, or independence of external analysis. Original role details have not been read.
Required materials and conditions: Each trial's funding, in-kind support, authors, analysis and roles
Materials to obtain first: Participation of study groups alone does not newly certify absence of company in-kind support or employee authors, or independence of external analysis. Original role details have not been read.
Further research: Obtain each trial's original support, products, affiliations, analysis and writing relationships.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Each trial's funding, in-kind support, authors, analysis and roles
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02 R04 R03 R05

N23 · What collection gaps remain for neutropenia, liver-related adverse events and QT prolongation?

Current findings: The stored safety record lists neutropenia, liver-related adverse events and QT prolongation; the parent's safety status is Caution.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new harm rates, grades, risk differences, P, CI, safety ranking or monitoring instructions are created. Original details of people or events, collection, denominators and relatedness have not been read.
Reason for missing information: No new harm rates, grades, risk differences, P, CI, safety ranking or monitoring instructions are created. Original details of people or events, collection, denominators and relatedness have not been read.
Required materials and conditions: Each harm's definition, grade, people or events, original denominators, exposure and relatedness
Materials to obtain first: No new harm rates, grades, risk differences, P, CI, safety ranking or monitoring instructions are created. Original details of people or events, collection, denominators and relatedness have not been read.
Further research: Obtain original harm types, grades, collection, group denominators, exposure, relatedness and discontinuation.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Each harm's definition, grade, people or events, original denominators, exposure and relatedness
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N24 · Are harm-related discontinuation, dose reduction, actual exposure and ITT distinguished?

Current findings: The stored summary records planned exposure of 3 years and ITT analysis, and describes harm types.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These do not support new calculations of exposure completion for everyone, discontinuation rates, adherent-participant effects or survival differences caused by harms.
Reason for missing information: These do not support new calculations of exposure completion for everyone, discontinuation rates, adherent-participant effects or survival differences caused by harms.
Required materials and conditions: Original discontinuation, dose reduction, adherence, exposure, harms and event mapping
Materials to obtain first: These do not support new calculations of exposure completion for everyone, discontinuation rates, adherent-participant effects or survival differences caused by harms.
Further research: Obtain original actual exposure, harm-related discontinuation, dose reduction, adherence, follow-up and event connections.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Original discontinuation, dose reduction, adherence, exposure, harms and event mapping
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02

N25 · Are rare or long-term harms and replication of harms in other drugs kept from being newly established?

Current findings: The currently designated stored summary records some harm types and still-immature OS, while other-drug trials are used as iDFS contrasts.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Absence of harm tables is not converted to absence of rare harms or long-term safety, and iDFS findings for other drugs do not certify identical harms. No treatment, monitoring or dose recommendations are created.
Reason for missing information: Absence of harm tables is not converted to absence of rare harms or long-term safety, and iDFS findings for other drugs do not certify identical harms. No treatment, monitoring or dose recommendations are created.
Required materials and conditions: Long-term harms, exposure, duration, denominators and direct drug-specific comparisons
Materials to obtain first: Absence of harm tables is not converted to absence of rare harms or long-term safety, and iDFS findings for other drugs do not certify identical harms. No treatment, monitoring or dose recommendations are created.
Further research: Obtain drug-specific direct harm, long-term exposure, collection, denominator and follow-up materials.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Long-term harms, exposure, duration, denominators and direct drug-specific comparisons
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02 R03 R04 R05

N26 · Are original registration, three bibliography URLs and two evidence records without bibliography distinguished?

Current findings: The three existing citations provide NATALEE interim and final URLs and a PENELOPE-B URL, while PALLAS and monarchE have only existing evidence-list information. Each original registration identifier is preserved.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new bibliography, DOI or URL is created for PALLAS or monarchE. External abstracts, full texts, registration, protocols and SAP remain unread; separate link testing was not performed.
Reason for missing information: No new bibliography, DOI or URL is created for PALLAS or monarchE. External abstracts, full texts, registration, protocols and SAP remain unread; separate link testing was not performed.
Required materials and conditions: Each report, existing links, registration identifiers and access status
Materials to obtain first: No new bibliography, DOI or URL is created for PALLAS or monarchE. External abstracts, full texts, registration, protocols and SAP remain unread; separate link testing was not performed.
Further research: Connect additional user-provided original materials by report type, bibliography and actual access status.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Each report, existing links, registration identifiers and access status
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02 R03 R04 R05

N27 · Are Korean and English articles, axes, reference dates, corrections, empty values and preparation status preserved?

Current findings: 2026-08-26, empty correction and deliberation records, the parent's B76/Caution, axes, Korean and English articles, subclaim B/D and notes are preserved as recorded.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Original B0, registration agreement and confirmatory wording are historical records, not new review certification. Subclaim absences are not filled; original pending-review or preparation-eligibility indicators are candidate history.
Reason for missing information: Original B0, registration agreement and confirmatory wording are historical records, not new review certification. Subclaim absences are not filled; original pending-review or preparation-eligibility indicators are candidate history.
Required materials and conditions: Distinguishing the entire parent, selected subclaim, original languages and history from the current preparation
Materials to obtain first: Original B0, registration agreement and confirmatory wording are historical records, not new review certification. Subclaim absences are not filled; original pending-review or preparation-eligibility indicators are candidate history.
Further research: Preserve original texts before connecting additional user materials or decisions as separate events.
Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification.
Conditions for verification: Distinguishing the entire parent, selected subclaim, original languages and history from the current preparation
Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries
Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety.
Referenced methods: Improved invasive disease-free survival

Related sources R01 R02